Xencor Reports Third Quarter 2021 Financial Results and Announces Encouraging Preliminary Data from Ongoing Phase 1 Study of Potency-reduced IL15-Fc Cytokine, XmAb306

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 7/30/2026

1. META
2. V
3. MSFT
4. PYPL
5. KLAC
6. SPY
7. CSGP
8. BE
9. SWKS
10. F

Go back to Xencor Reports Third Quarter 2021 Financial Results and Announces Encouraging Preliminary Data from Ongoing Phase 1 Study of Potency-reduced IL15-Fc Cytokine, XmAb306
XENCOR (NASDAQ: XNCR) Delayed: 19.53 -0.44 (2.2%)
Previous Close $19.97    52 Week High $26.50 
Open $19.93    52 Week Low $9.89 
Day High $20.12    P/E N/A 
Day Low $19.20    EPS $-0.51 
Volume 1,161,148